Premium
Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis
Author(s) -
Ahmed Ali Mahmoud,
Doheim Mohamed Fahmy,
Mattar Omar Mohamed,
Sherif Nourin Ali,
Truong Duy Hieu,
Hoa Pham T.L.,
Hirayama Kenji,
Huy Nguyen Tien
Publication year - 2018
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.24947
Subject(s) - daclatasvir , medicine , ribavirin , genotype , meta analysis , hepatitis c virus , virology , sofosbuvir , gastroenterology , hepatitis c , virus , biology , gene , biochemistry
Daclatasvir, asunaprevir (ASV), and beclabuvir (BCV) are direct‐acting antivirals (DAAs) for patients with hepatitis C virus genotype 1 infection. This systematic review and meta‐analysis investigating the efficacy and safety of this three‐drug combination in HCV genotype 1 infection. Eleven electronic search engines were searched for relevant publications. Studies were screened for eligibility and data was extracted. The outcomes were pooled as event rate and risk ratio (RR). The protocol was registered in PROSPERO (CRD42017054391). Among the included six studies, five studies were included for the meta‐analysis ( n = 1261). The three‐drug combination showed a high response rate in naïve patients with sustained virologic response at week‐12 posttreatment (SVR 12 ) rate = 95.7% (95%CI [93.8‐97.1]) and no difference detected by adding ribavirin (RBV) (the pooled RR = 0.98, 95%CI [0.90‐1.08], P = 0.70) or comparing with interferon‐experienced patients (RR = 1.02, 95%CI [0.98‐1.07], P = 0.31) regardless the genotype 1 subtypes or IL28B genotype. Treatment failure was minimal and showed no difference regarding the previous comparisons. Increasing the dose or the duration did not show a significant increase in the efficacy. In conclusion, this analysis showed high response rates in HCV genotype 1‐infected patients treated with daclatasvir, ASV, and BCV irrespective of RBV use, prior interferon‐based therapy, or restriction on non‐cirrhotic patients, IL28B genotype, or baseline resistance‐associated variants.